(MedPage Today) — The first interim safety results from a multicenter, safety surveillance study of Alzheimer’s disease patients treated with lecanemab (Leqembi) in real-world clinical practice were consistent with the known safety profile of…
Source link
Ad Banner
Show Comments (0)
Hide Comments (0)
Subscribe
Login
0 Comments
Oldest
